- Home
- AVBH vs ABEO Comparison
AVBH vs ABEO Comparison
Compare AVBH & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVBH | ABEO |
|---|---|---|
| Founded | 2003 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.5M | 281.0M |
| IPO Year | N/A | 1980 |
Fundamental Metrics
Financial Performance| Metric | AVBH | ABEO |
|---|---|---|
| Price | $27.15 | $5.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $29.17 | $18.20 |
| AVG Volume (30 Days) | 73.1K | ★ 1.2M |
| Earning Date | 10-23-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | ★ $22,129,000.00 | $400,000.00 |
| Revenue This Year | $19.35 | N/A |
| Revenue Next Year | $17.93 | $1,589.77 |
| P/E Ratio | ★ N/A | $4.24 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.75 | $3.93 |
| 52 Week High | $27.99 | $7.54 |
Technical Indicators
Market Signals| Indicator | AVBH | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 59.14 |
| Support Level | N/A | $4.80 |
| Resistance Level | N/A | $5.55 |
| Average True Range (ATR) | 0.00 | 0.26 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 80.75 |
Price Performance
Historical ComparisonAbout AVBH Avidbank Holdings Inc.
Avidbank Holdings Inc is a full-service commercial bank. It offers various services such as commercial and industrial lending, venture lending, structured finance, asset-based lending, sponsor finance, real estate construction, and commercial real estate lending.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.